Should Shire Buy NPS Pharmaceuticals?

Shire has reportedly become a hot buyout target because of its orphan drug pipeline and strong sales for its flagship drug Vyvanse. To stay independent, the company is reportedly considering making an acquisition of its own. Here is a Foolish look at one deal that is being widely discussed right now.

Jun 6, 2014 at 6:00PM

Acquisition season is apparently in full bloom in the health care sector with Shire (NASDAQ:SHPG)reportedly interested in making a deal for orphan drugmaker NPS Pharmaceuticals (NASDAQ:NPSP). According to a couple of sources, Shire has put a $5 billion credit facility into place with Citigroup and is considering an initial offer of $40 a share. 

When this rumor initially broke on May 30, NPS shares immediately ripped higher and are still up 21% in the past week. Even so, NPS's management was quick to pour cold water on this rumor by stating that they have not been contacted by Shire about a potential takeover.

NPSP Chart

NPSP data by YCharts

That said, I think the bigger question is whether a Shire-NPS pairing even makes sense in the first place? With this in mind, let's take a closer look at why Shire might be interested in this mid-cap biopharma.

Shire is reportedly a prime takeover target itself
Shire has a big target on its back and for good reasons. Firstly, the Dublin-based company offers potential acquirers the attractive low-tax Irish domicile.

Secondly, Shire has become a leader in the rare disease space following its acquisition of ViroPharma. Specifically, the company's orphan drug unit is now valued at over $2 billion following this acquisition. It's important to bear in mind that orphan drugs are highly prized in the pharma world because of their extended patent protection and high margins. And adding fuel to fire, Shire is seeing double-digit sales growth across many of its commercial products, including its flagship ADHD drug Vyvanse. 

All told, you can see why companies like Allergan have reportedly taken a deep interest in acquiring Shire and hence, why the company may want to make a decently sized acquisition of its own in an attempt to remain independent. 

NPS' earnings could triple next year 
Turning to the object of Shire's alleged desire, NPS offers an acquirer stellar growth potential in the rare disease space. The company is seeing double-digit sales growth for its treatment for Short Bowel Syndrome called Gattex and its licensing revenue remains strong. 

What could really make NPS a prime takeover target, however, is an approval for the company's treatment for hypoparathyroidism called Natpara. Hypoparathyroidism is a rare disorder that makes it difficult to metabolize calcium.

Natpara is presently scheduled to be reviewed by an Advisory Committee on July 24, followed by a Prescription Drug Fee User Act goal date of October 24. What's key to understand is that NPS' management believes that Natpara could become a major revenue driver for the company moving forward. Indeed, we've now seen forward EPS growth projections of close to 300% next year if Natpara can get past the FDA. 

Foolish wrap-up
I think one of the best reasons a Shire-NPS deal makes sense is that it would add to Shire's already formidable orphan drug portfolio. It's no secret that Shire has been building this portfolio with haste in its attempt to become less dependent upon Vyvanse revenue for growth.

Looking ahead, the question thus becomes, would this deal give Shire the protection its seeking from a potential acquirer? A Shire-NPS pairing would probably result in an entity with a market cap of around $40 billion and would make it the undisputed king of the orphan drug game. At that point, Allergan may not have the firepower to make a bid that would require a premium to make it attractive.

That said, I think this deal would actually make Shire an even more attractive takeover target and could whet the appetites of bigger pharmas. After all, it was Shire's last acquisition of ViroPharma that apparently began the buyout talk in the first place. In sum, if such an acquisition were to occur, it might not have the intended effect of helping Shire remain independent.  

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


George Budwell owns shares of NPS Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information